Tuesday, November 23, 2010

MS Community Welcomes Ampyra -- Or Does It?

As of September 30, some 31,000 folks with multiple sclerosis (MS) in the U.S. have tried the oral MS drug Ampyra, representing almost eight percent of all MS patients in this country, according to drug maker Acorda Therapeutics (ACOR-$26.25). In addition, the rate of “first refill” was 67 percent, based on weighted prescription trends going back to March.

“This is a significant penetration only seven months after commercial availability,” said Lauren Sabella, vice-president of commercial operations.

Ampyra (dalfampridine) is the first oral treatment prescribed to improve walking in patients with MS.

Are neurologists and patients readily embracing Ampyra, as claimed by management claim?
Read More at BNET….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

1 comment:

Daily Financial Markets said...

But It is totally awesome! I dont know how many publicly traded companies you look into, but I would like to tell you about one that I feel is trading ridiculously below fair value. It's name is China Wood Inc. symbol CNWD, its a freshly reverse merged china based company. If you review their latest 10Q you will see 42 million is assets, relatively no debt, 4.4 million in net profits for the quarter and 10 million outstanding shares. All of this and trading at $2.50! look into it and let me know what you think. Have a great day and I love your blog!